Lifang Yin
- Pharmaceutical Science top 0.2%
- Drug Solubulity and Delivery Systems 21
- Advanced Drug Delivery Systems 18
- Biomaterials top 0.5%
- Nanoparticle-Based Drug Delivery 48
- Molecular Medicine top 2%
- Drug Discovery top 1%
- Biomedical Engineering top 2%
- Nanoplatforms for cancer theranostics 25
-
- RNA Interference and Gene Delivery 25
- Advanced biosensing and bioanalysis techniques 8
-
- Drug Transport and Resistance Mechanisms 8
- Peptidase Inhibition and Analysis 8
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Lifang Yin
110 papers receiving 4.4k citations
Hit Papers
Peers
Comparison fields: 5 of 156
- Pharmaceutical Science 1.2k
- Biomaterials 1.6k
- Molecular Medicine 218
- Drug Discovery 7
- Biomedical Engineering 1.1k
Countries citing papers authored by Lifang Yin
This map shows the geographic impact of Lifang Yin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lifang Yin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lifang Yin more than expected).
Fields of papers citing papers by Lifang Yin
This network shows the impact of papers produced by Lifang Yin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lifang Yin. The network helps show where Lifang Yin may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Lifang Yin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 3 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 16 | |
| 5 | 2024 | 0 | |
| 6 | 2024 | 4 | |
| 7 | 2023 | 36 | |
| 8 | 2022 | 51 | |
| 9 | 2021 | 15 | |
| 10 | 2021 | 98 | |
| 11 | 2019 | 5 | |
| 12 | 2018 | 71 | |
| 13 | 2018 | 28 | |
| 14 | 2018 | 27 | |
| 15 | 2018 | 51 | |
| 16 | 2015 | 21 | |
| 17 | 2015 | 50 | |
| 18 | 2014 | 43 | |
| 19 | 2014 | 25 | |
| 20 | Preparation and formulation optimization of silymarin sustained-release tablets. | 2010 | 1 |
About Lifang Yin
Lifang Yin is a scholar working on Pharmaceutical Science, Biomaterials and Hepatology, having authored 120 papers that have together received 4.6k indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (48 papers), RNA Interference and Gene Delivery (25 papers), Nanoplatforms for cancer theranostics (25 papers), Drug Solubulity and Delivery Systems (21 papers), Advanced Drug Delivery Systems (18 papers), Drug Transport and Resistance Mechanisms (8 papers), Advanced biosensing and bioanalysis techniques (8 papers) and Peptidase Inhibition and Analysis (8 papers). The work is most often cited by research in Pharmaceutical Science (1.2k citations), Biomaterials (1.6k citations) and Molecular Medicine (218 citations). Lifang Yin has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Wei He, Yaqi Lv, Imran Shair Mohammad, Lifang Fan, Jianping Zhou, Yiao Wang, Jin Zhu, Shumin Zhu, Ke Yang and Wei He. Their work appears in journals such as ACS Nano, Biomaterials and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.